{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:00:25Z","timestamp":1784926825896,"version":"3.55.0"},"reference-count":76,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Testing for predictive biomarkers in lung cancer has evolved to integrate immunohistochemistry, tissue-based next-generation sequencing (NGS), and liquid biopsy. Tissue-based NGS remains the foundation for comprehensive genomic profiling, enabling detection of actionable mutations and guiding personalized therapies. RNA-based assays complement DNA testing by improving fusion detection. Liquid biopsy using circulating tumor DNA (ctDNA) offers a minimally invasive alternative for genotyping, monitoring treatment response, and assessing minimal residual disease, though sensitivity challenges persist in early-stage disease. Immunohistochemistry for PD-L1 and emerging antibody-drug conjugate targets further expands therapeutic options. Workflow optimization, including molecular tumor boards, reflex testing, and rapid assays, is critical to reduce turnaround times. Lastly, advances in digital pathology and AI promise novel biomarker discovery and integration into clinical practice, ensuring accurate interpretation and personalized treatment strategies in the rapidly evolving field of lung cancer personalized oncology.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000839","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:00:21Z","timestamp":1784923221000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Lung Cancer Biomarker Testing"],"prefix":"10.1097","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2701-6531","authenticated-orcid":false,"given":"Humberto E.","family":"Trejo Bittar","sequence":"first","affiliation":[{"name":"Department of Pathology and Translational Pathology, Moffit Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja E.","family":"Dacic","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7]]},"reference":[{"key":"R1-20260724","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jtho.2020.05.002","article-title":"The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer","volume":"15","author":"Smeltzer","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R2-20260724","doi-asserted-by":"crossref","first-page":"106034","DOI":"10.1016\/j.esmoop.2025.106034","article-title":"Global advances and future directions in lung cancer care: expert consensus and strategic priorities","volume":"11","author":"Meyer","year":"2026","journal-title":"ESMO Open"},{"key":"R3-20260724","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.jtho.2025.07.114","article-title":"The 2024 International Association for the Study of Lung Cancer Global Survey on Biomarker Testing","volume":"20","author":"Smeltzer","year":"2025","journal-title":"J Thorac Oncol"},{"key":"R4-20260724","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.3390\/curroncol29070396","article-title":"Consensus recommendations to optimize testing for new targetable alterations in non-small cell lung cancer","volume":"29","author":"Ionescu","year":"2022","journal-title":"Curr Oncol"},{"key":"R5-20260724","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jmoldx.2017.11.004","article-title":"Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology","volume":"20","author":"Lindeman","year":"2018","journal-title":"J Mol Diagn"},{"key":"R6-20260724","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.annonc.2025.08.003","article-title":"Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Zer","year":"2025","journal-title":"Ann Oncol"},{"key":"R7-20260724","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3343\/alm.2021.41.1.25","article-title":"Application of next generation sequencing in laboratory medicine","volume":"41","author":"Zhong","year":"2021","journal-title":"Ann Lab Med"},{"key":"R8-20260724","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1158\/1078-0432.CCR-19-0225","article-title":"High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden","volume":"25","author":"Benayed","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R9-20260724","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/dc.25067","article-title":"The basics of commonly used molecular techniques for diagnosis, and application of molecular testing in cytology","volume":"51","author":"Turner","year":"2023","journal-title":"Diagn Cytopathol"},{"key":"R10-20260724","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.jtho.2017.07.026","article-title":"MET exon 14 alterations and new resistance mutations to tyrosine kinase inhibitors: risk of inadequate detection with current amplicon-based NGS panels","volume":"12","author":"Poirot","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R11-20260724","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jmoldx.2021.03.001","article-title":"Clinical experience of cerebrospinal fluid-based liquid biopsy demonstrates superiority of cell-free DNA over cell pellet genomic DNA for molecular profiling","volume":"23","author":"Bale","year":"2021","journal-title":"J Mol Diagn"},{"key":"R12-20260724","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","article-title":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","volume":"24","author":"Gandara","year":"2018","journal-title":"Nat Med"},{"key":"R13-20260724","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1158\/1078-0432.CCR-19-0624","article-title":"Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer","volume":"25","author":"Leighl","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R14-20260724","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cllc.2021.10.001","article-title":"Clinical outcomes for plasma-based comprehensive genomic profiling versus standard-of-care tissue testing in advanced non-small cell lung cancer","volume":"23","author":"Page","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"R15-20260724","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jmoldx.2020.05.006","article-title":"Assessment of pre-analytical sample handling conditions for comprehensive liquid biopsy analysis","volume":"22","author":"Gerber","year":"2020","journal-title":"J Mol Diagn"},{"key":"R16-20260724","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1158\/1078-0432.CCR-17-3831","article-title":"Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies","volume":"24","author":"Odegaard","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R17-20260724","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jtho.2018.05.030","article-title":"Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC","volume":"13","author":"Rolfo","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R18-20260724","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41571-020-0423-x","article-title":"Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice","volume":"18","author":"Aggarwal","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"R19-20260724","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"key":"R20-20260724","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","article-title":"Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA","volume":"616","author":"Abbosh","year":"2023","journal-title":"Nature"},{"key":"R21-20260724","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.jtho.2016.05.036","article-title":"ctDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: the ASSESS Study","volume":"11","author":"Reck","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R22-20260724","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"key":"R23-20260724","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1158\/1078-0432.CCR-13-2482","article-title":"Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA","volume":"20","author":"Oxnard","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R24-20260724","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1200\/EDBK_237863","article-title":"Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices","volume":"39","author":"Pennell","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R25-20260724","doi-asserted-by":"crossref","first-page":"584","DOI":"10.21037\/tlcr.2019.09.18","article-title":"EGFR T790M detection rate in lung adenocarcinomas at baseline using droplet digital PCR and validation by ultra-deep next generation sequencing","volume":"8","author":"Lettig","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"R26-20260724","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1158\/1078-0432.CCR-14-2594","article-title":"Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy","volume":"21","author":"Mok","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R27-20260724","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.3390\/cancers17213474","article-title":"Liquid biopsy in lung cancer: tracking resistance to targeted therapies","volume":"17","author":"Urtecho","year":"2025","journal-title":"Cancers (Basel)"},{"key":"R28-20260724","doi-asserted-by":"crossref","first-page":"13379","DOI":"10.1038\/s41598-018-30780-4","article-title":"The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis","volume":"8","author":"Passiglia","year":"2018","journal-title":"Sci Rep"},{"key":"R29-20260724","doi-asserted-by":"crossref","first-page":"10462","DOI":"10.3390\/ijms262110462","article-title":"Prevalence of histological transformation in first-line osimertinib non-small cell lung cancers: case series and literature review","volume":"26","author":"Sparavelli","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R30-20260724","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.annonc.2023.11.008","article-title":"Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer","volume":"35","author":"Tran","year":"2024","journal-title":"Ann Oncol"},{"key":"R31-20260724","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s43018-020-0096-5","article-title":"Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab","volume":"1","author":"Bratman","year":"2020","journal-title":"Nat Cancer"},{"key":"R32-20260724","doi-asserted-by":"crossref","first-page":"108528","DOI":"10.1016\/j.lungcan.2025.108528","article-title":"ctDNA can detect minimal residual disease in curative treated non-small cell lung cancer patients using a tumor agnostic approach","volume":"203","author":"Rosenlund","year":"2025","journal-title":"Lung Cancer"},{"key":"R33-20260724","doi-asserted-by":"crossref","first-page":"103899","DOI":"10.1016\/j.critrevonc.2022.103899","article-title":"Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: making the invisible visible","volume":"182","author":"Gristina","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"R34-20260724","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov"},{"key":"R35-20260724","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3390\/cells14171312","article-title":"Utility and future perspectives of circulating tumor DNA analysis in non-small cell lung cancer patients in the era of perioperative chemo-immunotherapy","volume":"14","author":"Ohara","year":"2025","journal-title":"Cells"},{"key":"R36-20260724","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.annonc.2022.02.007","article-title":"Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer","volume":"33","author":"Gale","year":"2022","journal-title":"Ann Oncol"},{"key":"R37-20260724","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/1878-0261.13387","article-title":"Postoperative circulating tumor DNA can refine risk stratification in resectable lung cancer: results from a multicenter study","volume":"17","author":"Fu","year":"2023","journal-title":"Mol Oncol"},{"key":"R38-20260724","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/1078-0432.CCR-09-2845","article-title":"A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry","volume":"16","author":"Mino-Kenudson","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R39-20260724","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41379-019-0324-7","article-title":"NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls","volume":"33","author":"Solomon","year":"2020","journal-title":"Mod Pathol"},{"key":"R40-20260724","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/annonc\/mdz204","article-title":"ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research","volume":"30","author":"Marchio","year":"2019","journal-title":"Ann Oncol"},{"key":"R41-20260724","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jtho.2015.10.025","article-title":"HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers","volume":"11","author":"Li","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R42-20260724","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/PO.19.00333","article-title":"Targeting HER2 alterations in non-small-cell lung cancer: a comprehensive review","volume":"4","author":"Zhao","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"R43-20260724","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.5858\/arpa.2016-0331-CP","article-title":"HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology","volume":"140","author":"Bartley","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"R44-20260724","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"R45-20260724","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol"},{"key":"R46-20260724","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY Trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J Clin Oncol"},{"key":"R47-20260724","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jtho.2025.08.014","article-title":"MTAP expression by immunohistochemistry: a novel biomarker in NSCLC","volume":"21","author":"Brune","year":"2026","journal-title":"J Thorac Oncol"},{"key":"R48-20260724","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jtho.2023.10.004","article-title":"Microsatellite instability and mismatch repair deficiency define a distinct subset of lung cancers characterized by smoking exposure, high tumor mutational burden, and recurrent somatic MLH1 inactivation","volume":"19","author":"Yang","year":"2024","journal-title":"J Thorac Oncol"},{"key":"R49-20260724","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"J Thorac Oncol"},{"key":"R50-20260724","doi-asserted-by":"crossref","first-page":"933","DOI":"10.5858\/arpa.2020-0119-CP","article-title":"Collection and Handling of Thoracic Small Biopsy and Cytology Specimens for Ancillary Studies: Guideline From the College of American Pathologists in Collaboration With the American College of Chest Physicians, Association for Molecular Pathology, American Society of Cytopathology, American Thoracic Society, Pulmonary Pathology Society, Papanicolaou Society of Cytopathology, Society of Interventional Radiology, and Society of Thoracic Radiology","volume":"144","author":"Roy-Chowdhuri","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"R51-20260724","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jtho.2018.12.005","article-title":"Best practices recommendations for diagnostic immunohistochemistry in lung cancer","volume":"14","author":"Yatabe","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R52-20260724","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1158\/1078-0432.CCR-15-2946","article-title":"Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets","volume":"22","author":"Rekhtman","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R53-20260724","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1146\/annurev-pathmechdis-042524-023153","article-title":"Molecular subtypes of neuroendocrine carcinoma: from chaos to consensus","volume":"21","author":"Wang","year":"2025","journal-title":"Annu Rev Pathol"},{"key":"R54-20260724","doi-asserted-by":"crossref","first-page":"101587","DOI":"10.1016\/j.esmoop.2023.101587","article-title":"Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation","volume":"8","author":"Gosney","year":"2023","journal-title":"ESMO Open"},{"key":"R55-20260724","first-page":"100077","article-title":"Ultrarapid EGFR mutation screening followed by comprehensive next-generation sequencing: a feasible, informative approach for lung carcinoma cytology specimens with a high success rate","volume":"1","author":"Arcila","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"R56-20260724","doi-asserted-by":"crossref","first-page":"e22930","DOI":"10.1002\/cncy.22930","article-title":"Same-day molecular testing for targetable mutations in solid tumor cytopathology-The next frontier of the rapid on-site evaluation","volume":"133","author":"Iorgulescu","year":"2025","journal-title":"Cancer Cytopathol"},{"key":"R57-20260724","doi-asserted-by":"crossref","first-page":"e22925","DOI":"10.1002\/cncy.22925","article-title":"A rapid turnaround time workflow for a cytological liquid biopsy assay using FNA supernatant specimens","volume":"133","author":"Maher","year":"2025","journal-title":"Cancer Cytopathol"},{"key":"R58-20260724","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2159-8290.CD-14-1236","article-title":"Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities","volume":"5","author":"Skoulidis","year":"2015","journal-title":"Cancer Discov"},{"key":"R59-20260724","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/1078-0432.CCR-24-2310","article-title":"Impact of co-mutations and transcriptional signatures in non-small cell lung cancer patients treated with adagrasib in the KRYSTAL-1 trial","volume":"31","author":"Negrao","year":"2025","journal-title":"Clin Cancer Res"},{"key":"R60-20260724","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1158\/2159-8290.CD-22-1420","article-title":"Comutations and KRASG12C inhibitor efficacy in advanced NSCLC","volume":"13","author":"Negrao","year":"2023","journal-title":"Cancer Discov"},{"key":"R61-20260724","doi-asserted-by":"crossref","first-page":"108887","DOI":"10.1016\/j.lungcan.2025.108887","article-title":"Optimizing communication for ultrafast lung cancer biomarker testing: the UTOPIA pilot study","volume":"211","author":"Hernandez","year":"2026","journal-title":"Lung Cancer"},{"key":"R62-20260724","doi-asserted-by":"crossref","first-page":"e2325332","DOI":"10.1001\/jamanetworkopen.2023.25332","article-title":"Association of circulating tumor dna testing before tissue diagnosis with time to treatment among patients with suspected advanced lung cancer: the ACCELERATE Nonrandomized Clinical Trial","volume":"6","author":"Garcia-Pardo","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R63-20260724","first-page":"100301","article-title":"Plasma genotyping at the time of diagnostic tissue biopsy decreases time-to-treatment in patients with advanced NSCLC-results from a prospective pilot study","volume":"3","author":"Thompson","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"R64-20260724","doi-asserted-by":"crossref","first-page":"e2300535","DOI":"10.1200\/PO.23.00535","article-title":"Liquid biopsy of lung cancer before pathological diagnosis is associated with shorter time to treatment","volume":"8","author":"Russo","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"R65-20260724","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jtho.2024.12.011","article-title":"LIBELULE: a randomized phase iii study to evaluate the clinical relevance of early liquid biopsy in patients with suspicious metastatic lung cancer","volume":"20","author":"Swalduz","year":"2025","journal-title":"J Thorac Oncol"},{"key":"R66-20260724","doi-asserted-by":"crossref","first-page":"17588359251405616","DOI":"10.1177\/17588359251405616","article-title":"A cost-effectiveness analysis model of actionable genomic alteration testing strategies incorporating different modalities and sizes of next-generation sequencing panels in non-small-cell lung cancer","volume":"17","author":"Ang","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"R67-20260724","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/s41591-018-0177-5","article-title":"Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning","volume":"24","author":"Coudray","year":"2018","journal-title":"Nat Med"},{"key":"R68-20260724","doi-asserted-by":"crossref","first-page":"6695","DOI":"10.1038\/s41467-023-42453-6","article-title":"Validation of MSIntuit as an AI-based pre-screening tool for MSI detection from colorectal cancer histology slides","volume":"14","author":"Saillard","year":"2023","journal-title":"Nat Commun"},{"key":"R69-20260724","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1038\/s41379-022-01141-4","article-title":"Direct identification of ALK and ROS1 fusions in non-small cell lung cancer from hematoxylin and eosin-stained slides using deep learning algorithms","volume":"35","author":"Mayer","year":"2022","journal-title":"Mod Pathol"},{"key":"R70-20260724","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1111\/1759-7714.14694","article-title":"Application of several machine learning algorithms for the prediction of afatinib treatment outcome in advanced-stage EGFR-mutated non-small-cell lung cancer","volume":"13","author":"Kim","year":"2022","journal-title":"Thorac Cancer"},{"key":"R71-20260724","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.1038\/s41598-023-31284-6","article-title":"Predicting EGFR mutational status from pathology images using a real-world dataset","volume":"13","author":"Pao","year":"2023","journal-title":"Sci Rep"},{"key":"R72-20260724","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1016\/S2589-7500(22)00024-3","article-title":"Mining whole-lung information by artificial intelligence for predicting EGFR genotype and targeted therapy response in lung cancer: a multicohort study","volume":"4","author":"Wang","year":"2022","journal-title":"Lancet Digit Health"},{"key":"R73-20260724","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study","volume":"43","author":"Ahn","year":"2025","journal-title":"J Clin Oncol"},{"key":"R74-20260724","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1038\/s41467-020-18613-3","article-title":"Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy","volume":"11","author":"Kato","year":"2020","journal-title":"Nat Commun"},{"key":"R75-20260724","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.jtho.2025.07.009","article-title":"Molecular tumor boards: a consensus statement from the International Association for the Study of Lung Cancer","volume":"20","author":"Aldea","year":"2025","journal-title":"J Thorac Oncol"},{"key":"R76-20260724","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.annonc.2025.02.009","article-title":"ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice","volume":"36","author":"Westphalen","year":"2025","journal-title":"Ann Oncol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:00:29Z","timestamp":1784923229000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000839"}},"subtitle":["IHC, Tissue Genomics, Digital Pathology, and ctDNA"],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":76,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000839","relation":{},"ISSN":["1540-336X"],"issn-type":[{"value":"1540-336X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-01-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}